EXPRES2ION
ExpreS2ion Biotechnologies is a biotech company within protein production in Drosophila Schneider-2 (S2) cells.
EXPRES2ION
Industry:
Biotechnology Medical
Founded:
2010-01-01
Address:
Hørsholm, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.expres2ionbio.com
Total Employee:
11+
Status:
Active
Contact:
+45 2222 1019
Email Addresses:
info@expres2ionbio.cominvestor@expres2ionbio.com
buf@expres2ionbio.com
ka@expres2ionbio.com
Total Funding:
2.7 M SEK
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
AI4R
AI4R engages in digital real-time autoradiography, a new-generation imaging solutions for preclinical studies.
DNAlytics
DNAlytics develops innovative data-driven precision medicine solutions.
Gate2Brain
Gate2Brain is a biotech company to improve drug delivery with peptide-based patented technology.
OmniSpirant
OmniSpirant develops regenerative gene therapies with the potential to transform respiratory medicine.
Current Employees Featured
Martin Roland Jensen Executive Chairman & Co-Founder @ ExpreS2ion
Executive Chairman & Co-Founder
Founder
Investors List
Horizon 2020
Horizon 2020 investment in Grant - ExpreS2ion
Official Site Inspections
http://www.expres2ionbio.com Semrush global rank: 2.56 M Semrush visits lastest month: 6.88 K
- Host name: linux118.unoeuro.com
- IP address: 94.231.103.63
- Location: Denmark
- Latitude: 55.7123
- Longitude: 12.0564
- Timezone: Europe/Copenhagen
More informations about "ExpreS2ion"
Company - ExpreS2ion Biotechnologies
Info@expres2ionbio.com +45 22 22 10 19. Holding Company ExpreS2ion Biotech Holding AB: Registration number: 559033-3729 c/o Mindpark Rönnowsgatan 8C SE-252 25 Helsingborg, …See details»
ExpreS2ion Biotechnologies - Wikipedia
ExpreS2ion Biotechnologies is a Danish biotechnology company specialised in the development of new vaccines and immunotherapy products based in Hørsholm, Denmark and listed on the Nasdaq First North Growth Market Sweden. ExpreS2ion is part of the PREVENT-nCoV consortium comprising AdaptVac (a joint-venture between ExpreS2ion Biotechnologies and the University of CopenhagenSee details»
ExpreS2ion - Crunchbase Company Profile & Funding
Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel …See details»
Annual Report 2020 Proteins for life - investor.expres2ionbio.com
10 Organization structure 11 Joint Venture 12 Partners 13 CEO letter Business Update 15 2020 timeline of key events 16 Pipeline 19 Near-term outlook Corporate matters 21 Management …See details»
Annual report 2019 - investor.expres2ionbio.com
3 About ExpreS2ion Biotech Holding AB ExpreS2ion was established in 2010 as a technology spinout from the Danish pharmaceutical company Affitech A/S (formerly known as Pharmexa …See details»
ExpreS2ion Biotechnologies - LinkedIn
Investor.expres2ionbio.com 15 1 Comment Like Comment Share ExpreS2ion Biotechnologies 3,223 followers 1mo Report this post ExpreS2ion Biotech Q2 2024 Update and Financial …See details»
innovative vaccines for a healthier world - ExpreS2ion …
EXPRES2ION 2024 FIRST QUARTER INTERIM REPORT Company structure ExpreS2ion Biotech Holding AB is a limited company which has been listed on the Nasdaq First NorthSee details»
Investors & Partners - ExpreS2ion Biotechnologies
Holding Company ExpreS2ion Biotech Holding AB: Registration number: 559033-3729 c/o Mindpark Rönnowsgatan 8C SE-252 25 Helsingborg, SwedenSee details»
ExpreS2ion Biotechnologies | DANISH BIO – DANSK BIOTEK
ExpreS 2 ion combines a unique production platform, ExpreS 2, for fast and efficient development of new therapeutics and diagnostics, and a universal capsid virus-like particle (cVLP) …See details»
ExpreS2ion strengthens its organization to further accelerate its ...
Jan 11, 2021 ExpreS2ion strengthens its organization to further accelerate its pipeline project development Mon, Jan 11, 2021 08:30 CET Report this content Hørsholm, Denmark, January …See details»
Proteins for life - ExpreS2ion Biotechnologies
EXPRES2ION HALF-YEAR REPORT Q2 2022 Definitions “ExpreS2ion !iotech Holding A!” refers to ExpreS2ion Biotech Holding AB with corporate identity number 559033-3729. “The …See details»
ExpreS2ion to present in upcoming investor and scientific events
Oct 31, 2024 E-mail: investor@expres2ionbio.com . About ExpreS2ion ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to …See details»
Expres2ion Biotech - Products, Competitors, Financials, Employees ...
Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel …See details»
ExpreS2ion Biotechnologies - innovative vaccines for a healthier …
Organization, aimed at extending our financial runway. This strategic review led to the evaluation of the ES2B-C001 breast A word from our CEO “We've commenced 2024 equipped with a …See details»
Proprietary Pipeline - ExpreS2ion Biotechnologies
Info@expres2ionbio.com +45 22 22 10 19. Holding Company ExpreS2ion Biotech Holding AB: Registration number: 559033-3729 c/o Mindpark Rönnowsgatan 8C SE-252 25 Helsingborg, …See details»
Disease focus - ExpreS2ion Biotechnologies
New research led by the World Health Organization has found that vaccines have saved an estimated 154 million lives in the past 50 years from 14 different diseases. Most of these have …See details»
CRO services - ExpreS2ion Biotechnologies
Our CRO services include: Fee-for-service contract research and products related to recombinant protein expression. Outlicensing the ExpreS2 platform to research institutes and …See details»
Platform - ExpreS2ion Biotechnologies
Info@expres2ionbio.com +45 22 22 10 19. Holding Company ExpreS2ion Biotech Holding AB: Registration number: 559033-3729 c/o Mindpark Rönnowsgatan 8C SE-252 25 Helsingborg, …See details»
Revolutionizing breast cancer treatment: ES2B-C001
Buf@expres2ionbio.com. ka@expres2ionbio.com. buf@expres2ionbio.com. OCK BIOTECH . BIOTECH . 100 50 100 200 300 400 500 600 . MEDICAL UNIVERSITY | OF VIENNA …See details»